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There is a substantial gap between the levels of enzyme activity Nature can evolve and those that scientists can 
engineer in the lab. This suggests that conventional directed evolution techniques involving incremental 
improvements in enzyme activity may frequently fail to ascend even local fitness maxima. This is most likely due 
to an inability of step-wise evolutionary approaches to effectively retain mutations that are beneficial in 
combination with one another, but on an individual basis are neutral or even slightly deleterious (i.e., exhibit 
positive epistasis). To overcome this limitation, we are seeking to “jump” straight to an enzyme with peak activity 
by conducting simultaneous mass randomisation of eight key active site residues in Escherichia coli NfsA, a 
nitroreductase enzyme that has several diverse applications in biotechnology. Using degenerate codons, we 
generated a diverse library containing 425 million unique variants. We then applied a powerful selection system 
using either or both of two recently identified positive selection compounds, which has enabled us to recover a 
diverse range of highly active nitroreductase variants. These have been screened against a panel of prodrug 
substrates to identify variants that are improved with specific prodrug substrates of interest. A primary focus has 
been developing nitroreductases as tools for targeted cell ablation in zebrafish. The basic system involves co-
expression of a nitroreductase and fluorescent reporter under the control of a cell type specific promoter in a 
transgenic fish. Expression of the nitroreductase selectively sensitises target cells to a prodrug which, following 
nitroreduction, yields a cytotoxic compound that causes precise targeted cell ablation. We have identified 
several nil-bystander prodrugs that are able to selectively ablate nitroreductase expressing cells with no harm to 
nearby cells, and have paired these with highly specialised NfsA variants to improve the efficacy and accuracy 
of cell ablation. We have also screened our mass-randomisation libraries to recover nitroreductases that have 
non-overlapping prodrug specificities, to be used in a multiplex cell ablation system. This expands upon the 
previous system, by using pairs of selective nitroreductases and two different prodrugs to facilitate independent 
ablation of multiple cell types. For example, we have identified a specialist NfsA variant that has activity for 
tinidazole and not for metronidazole, achieved by including metronidazole as a simultaneous counter-selection 
during the initial positive selection process. This elegant positive/negative selection eliminated activity with 
metronidazole, while still ensuring that some level of nitroreductase activity was retained overall.  
 
